Disease · MONDO_0019324
pemphigus foliaceus
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. pemphigus foliaceus. Diseases, record MONDO_0019324. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0019324
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs3
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| EFGARTIGIMOD ALFA | CHEMBL4297551 | Protein | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| RILZABRUTINIB | CHEMBL3702854 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ORILANOLIMAB | CHEMBL4298117 | Antibody | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets2
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| FCGRT | IgG receptor FcRn large subunit p51 | 2 | IgG receptor FcRn large subunit p51 antagonist | Phase 3 | https://conductscience.org/library/genes/2217 | Drugs and targets |
| BTK | Tyrosine-protein kinase BTK | 1 | Tyrosine-protein kinase BTK inhibitor | Phase 3 | https://conductscience.org/library/genes/695 | Drugs and targets |
Trials5
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04598451 | A Study to Assess the Efficacy and Safety of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus) | Phase 3 | 222 | 2024-10-01 | Pemphigus Vulgaris, Pemphigus Foliaceus | EFGARTIGIMOD ALFA | Its record names the disease | ClinicalTrials.gov |
| NCT04598477 | A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus) | Phase 3 | 183 | 2025-03-30 | Pemphigus Vulgaris, Pemphigus Foliaceus | EFGARTIGIMOD ALFA | Its record names the disease | ClinicalTrials.gov |
| NCT03762265 | A Study of PRN1008 in Patients With Pemphigus | Phase 3 | 131 | 2022-09-21 | Pemphigus | RILZABRUTINIB | Its record names the disease | ClinicalTrials.gov |
| NCT03075904 | A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus) | Phase 1/2 | 8 | 2020-02-05 | Pemphigus, Pemphigus Vulgaris, Pemphigus Foliaceus | ORILANOLIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03334058 | A Study to Evaluate the Safety, PD, PK and Efficacy of ARGX-113 in Patients With Pemphigus | Phase 2 | 34 | Pemphigus Vulgaris, Pemphigus Foliaceus | EFGARTIGIMOD ALFA | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials9
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
Efgartigimod PH20 SC vs Placebo PH20 SC: Number of Pemphigus Vulgaris (PV) and Pemphigus Foliaceus (PF) Participants Who Achieve Complete Clinical Remission (CR) on Minimal Prednisone Therapy Within 30 Weeks | 55 of 147 | 24 of 75 | 222 | NCT04598451 | Trial comparisons |
| Efgartigimod PH20 SC vs Placebo PH20 SC: deaths from any cause | 0 of 147 | 0 of 75 | 222 | NCT04598451 | Trial comparisons |
| Efgartigimod PH20 SC vs Placebo PH20 SC: serious adverse events | 18 of 147 | 10 of 75 | 222 | NCT04598451 | Trial comparisons |
| Efgartigimod PH20 SC vs Placebo PH20 SC: Number of Pemphigus Vulgaris (PV) Participants Who Achieve Complete Clinical Remission (CR) on Minimal Prednisone Therapy | 44 of 124 | 20 of 66 | 190 | NCT04598451 | Trial comparisons |
| Efgartigimod-efgartigimod PH20 SC vs Placebo-efgartigimod PH20 SC: Proportion of Participants With Pemphigus Vulgaris (PV) and Pemphigus Foliaceus (PF) Who Achieve CRmin | 55 of 101 | 26 of 48 | 149 | NCT04598477 | Trial comparisons |
| Efgartigimod-efgartigimod PH20 SC vs Placebo-efgartigimod PH20 SC: Rate of Treatment Failure in Participants With PV and PF | 3 of 101 | 1 of 48 | 149 | NCT04598477 | Trial comparisons |
| Efgartigimod-efgartigimod PH20 SC vs Placebo-efgartigimod PH20 SC: deaths from any cause | 0 of 101 | 1 of 48 | 149 | NCT04598477 | Trial comparisons |
| Efgartigimod-efgartigimod PH20 SC vs Placebo-efgartigimod PH20 SC: serious adverse events | 16 of 101 | 4 of 48 | 149 | NCT04598477 | Trial comparisons |
| Efgartigimod-efgartigimod PH20 SC vs Placebo-efgartigimod PH20 SC: Proportion of Participants With Pemphigus Vulgaris (PV) Who Achieve CRmin | 47 of 86 | 22 of 41 | 127 | NCT04598477 | Trial comparisons |
Papers from its trials4
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0019324
GET https://conductscience.org/api/diseases/v1/MONDO_0019324/drugs